These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

251 related items for PubMed ID: 16467101

  • 1. Mannan-MUC1-pulsed dendritic cell immunotherapy: a phase I trial in patients with adenocarcinoma.
    Loveland BE, Zhao A, White S, Gan H, Hamilton K, Xing PX, Pietersz GA, Apostolopoulos V, Vaughan H, Karanikas V, Kyriakou P, McKenzie IF, Mitchell PL.
    Clin Cancer Res; 2006 Feb 01; 12(3 Pt 1):869-77. PubMed ID: 16467101
    [Abstract] [Full Text] [Related]

  • 2. Mannan mucin-1 peptide immunization: influence of cyclophosphamide and the route of injection.
    Karanikas V, Thynne G, Mitchell P, Ong CS, Gunawardana D, Blum R, Pearson J, Lodding J, Pietersz G, Broadbent R, Tait B, McKenzie IF.
    J Immunother; 2001 Feb 01; 24(2):172-83. PubMed ID: 11265775
    [Abstract] [Full Text] [Related]

  • 3. A pilot clinical trial of vaccination with dendritic cells pulsed with autologous tumor cells derived from malignant pleural effusion in patients with late-stage lung carcinoma.
    Chang GC, Lan HC, Juang SH, Wu YC, Lee HC, Hung YM, Yang HY, Whang-Peng J, Liu KJ.
    Cancer; 2005 Feb 15; 103(4):763-71. PubMed ID: 15637694
    [Abstract] [Full Text] [Related]

  • 4. Dendritic cell-based immunotherapy of cancer with carcinoembryonic antigen-derived, HLA-A24-restricted CTL epitope: Clinical outcomes of 18 patients with metastatic gastrointestinal or lung adenocarcinomas.
    Ueda Y, Itoh T, Nukaya I, Kawashima I, Okugawa K, Yano Y, Yamamoto Y, Naitoh K, Shimizu K, Imura K, Fuji N, Fujiwara H, Ochiai T, Itoi H, Sonoyama T, Hagiwara A, Takesako K, Yamagishi H.
    Int J Oncol; 2004 Apr 15; 24(4):909-17. PubMed ID: 15010829
    [Abstract] [Full Text] [Related]

  • 5. Antibody and T cell responses of patients with adenocarcinoma immunized with mannan-MUC1 fusion protein.
    Karanikas V, Hwang LA, Pearson J, Ong CS, Apostolopoulos V, Vaughan H, Xing PX, Jamieson G, Pietersz G, Tait B, Broadbent R, Thynne G, McKenzie IF.
    J Clin Invest; 1997 Dec 01; 100(11):2783-92. PubMed ID: 9389743
    [Abstract] [Full Text] [Related]

  • 6. Clinical evaluation of dendritic cell vaccination for patients with recurrent glioma: results of a clinical phase I/II trial.
    Yamanaka R, Homma J, Yajima N, Tsuchiya N, Sano M, Kobayashi T, Yoshida S, Abe T, Narita M, Takahashi M, Tanaka R.
    Clin Cancer Res; 2005 Jun 01; 11(11):4160-7. PubMed ID: 15930352
    [Abstract] [Full Text] [Related]

  • 7. A phase-I trial using a universal GM-CSF-producing and CD40L-expressing bystander cell line (GM.CD40L) in the formulation of autologous tumor cell-based vaccines for cancer patients with stage IV disease.
    Dessureault S, Noyes D, Lee D, Dunn M, Janssen W, Cantor A, Sotomayor E, Messina J, Antonia SJ.
    Ann Surg Oncol; 2007 Feb 01; 14(2):869-84. PubMed ID: 17103257
    [Abstract] [Full Text] [Related]

  • 8. Phase I study of immunization with dendritic cells modified with fowlpox encoding carcinoembryonic antigen and costimulatory molecules.
    Morse MA, Clay TM, Hobeika AC, Osada T, Khan S, Chui S, Niedzwiecki D, Panicali D, Schlom J, Lyerly HK.
    Clin Cancer Res; 2005 Apr 15; 11(8):3017-24. PubMed ID: 15837756
    [Abstract] [Full Text] [Related]

  • 9. Dendritic cells loaded with killed allogeneic melanoma cells can induce objective clinical responses and MART-1 specific CD8+ T-cell immunity.
    Palucka AK, Ueno H, Connolly J, Kerneis-Norvell F, Blanck JP, Johnston DA, Fay J, Banchereau J.
    J Immunother; 2006 Apr 15; 29(5):545-57. PubMed ID: 16971810
    [Abstract] [Full Text] [Related]

  • 10. Immunologic and clinical effects of injecting mature peptide-loaded dendritic cells by intralymphatic and intranodal routes in metastatic melanoma patients.
    Lesimple T, Neidhard EM, Vignard V, Lefeuvre C, Adamski H, Labarrière N, Carsin A, Monnier D, Collet B, Clapisson G, Birebent B, Philip I, Toujas L, Chokri M, Quillien V.
    Clin Cancer Res; 2006 Dec 15; 12(24):7380-8. PubMed ID: 17189411
    [Abstract] [Full Text] [Related]

  • 11. [Efficacy of autologous renal tumor cell lysate-loaded dendritic cell vaccine in combination with cytokine-induced killer cells on advanced renal cell carcinoma--a report of ten cases].
    Wang H, Zhou FJ, Wang QJ, Qin ZK, Huang LX, Liu ZW, Han H, Li YQ, Chen SP, Xia JC.
    Ai Zheng; 2006 May 15; 25(5):625-30. PubMed ID: 16687087
    [Abstract] [Full Text] [Related]

  • 12. Treatment with autologous antigen-presenting cells activated with the HER-2 based antigen Lapuleucel-T: results of a phase I study in immunologic and clinical activity in HER-2 overexpressing breast cancer.
    Park JW, Melisko ME, Esserman LJ, Jones LA, Wollan JB, Sims R.
    J Clin Oncol; 2007 Aug 20; 25(24):3680-7. PubMed ID: 17704416
    [Abstract] [Full Text] [Related]

  • 13. Dendritic cell vaccine immunotherapy of cancer targeting MUC1 mucin.
    Kontani K, Taguchi O, Ozaki Y, Hanaoka J, Sawai S, Inoue S, Abe H, Hanasawa K, Fujino S.
    Int J Mol Med; 2003 Oct 20; 12(4):493-502. PubMed ID: 12964025
    [Abstract] [Full Text] [Related]

  • 14. Immunization with Melan-A peptide-pulsed peripheral blood mononuclear cells plus recombinant human interleukin-12 induces clinical activity and T-cell responses in advanced melanoma.
    Peterson AC, Harlin H, Gajewski TF.
    J Clin Oncol; 2003 Jun 15; 21(12):2342-8. PubMed ID: 12805336
    [Abstract] [Full Text] [Related]

  • 15. Analysis and characterization of antitumor T-cell response after administration of dendritic cells loaded with allogeneic tumor lysate to metastatic melanoma patients.
    Bercovici N, Haicheur N, Massicard S, Vernel-Pauillac F, Adotevi O, Landais D, Gorin I, Robert C, Prince HM, Grob JJ, Leccia MT, Lesimple T, Wijdenes J, Bartholeyns J, Fridman WH, Salcedo M, Ferries E, Tartour E.
    J Immunother; 2008 Jan 15; 31(1):101-12. PubMed ID: 18157017
    [Abstract] [Full Text] [Related]

  • 16. Glioblastoma patients exhibit circulating tumor-specific CD8+ T cells.
    Tang J, Flomenberg P, Harshyne L, Kenyon L, Andrews DW.
    Clin Cancer Res; 2005 Jul 15; 11(14):5292-9. PubMed ID: 16033848
    [Abstract] [Full Text] [Related]

  • 17. Flow cytometric measurement of intracellular cytokines detects immune responses in MUC1 immunotherapy.
    Karanikas V, Lodding J, Maino VC, McKenzie IF.
    Clin Cancer Res; 2000 Mar 15; 6(3):829-37. PubMed ID: 10741704
    [Abstract] [Full Text] [Related]

  • 18. Dendritic cell vaccination in glioblastoma patients induces systemic and intracranial T-cell responses modulated by the local central nervous system tumor microenvironment.
    Liau LM, Prins RM, Kiertscher SM, Odesa SK, Kremen TJ, Giovannone AJ, Lin JW, Chute DJ, Mischel PS, Cloughesy TF, Roth MD.
    Clin Cancer Res; 2005 Aug 01; 11(15):5515-25. PubMed ID: 16061868
    [Abstract] [Full Text] [Related]

  • 19. Blood dendritic cells generated with Flt3 ligand and CD40 ligand prime CD8+ T cells efficiently in cancer patients.
    Davis ID, Chen Q, Morris L, Quirk J, Stanley M, Tavarnesi ML, Parente P, Cavicchiolo T, Hopkins W, Jackson H, Dimopoulos N, Tai TY, MacGregor D, Browning J, Svobodova S, Caron D, Maraskovsky E, Old LJ, Chen W, Cebon J.
    J Immunother; 2006 Aug 01; 29(5):499-511. PubMed ID: 16971806
    [Abstract] [Full Text] [Related]

  • 20. Combination therapy with tumor cell-pulsed dendritic cells and activated lymphocytes for patients with disseminated carcinomas.
    Katano M, Morisaki T, Koga K, Nakamura M, Onishi H, Matsumoto K, Tasaki A, Nakashima H, Akiyoshi T, Nakamura M.
    Anticancer Res; 2005 Aug 01; 25(6A):3771-6. PubMed ID: 16302738
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 13.